Belite Bio, Inc (BLTE) Current Ratio
- Current ratio · latest quarter: Value 50.02×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2025-12-31; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 50.02× | Current assets / current liabilities. $494.27M ÷ $9.88M ≈ 50.02× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 494.27M USD | Assets, Current |
| Current obligations | 9.88M USD | Liabilities, Current |
| Cash and equivalents | 352.93M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | Debt Securities, Available-for-sale, Current |
| Customer receivables | (m) | |
| Inventory | (m) | |
| Payables | (m) | |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | $494.27M | $9.88M | $352.93M | (m) | (m) | (m) | (m) | (m) | 50.02× |
| 2024-12-31 | $147.07M | $6.05M | $31.68M | $4.55M | (m) | (m) | (m) | (m) | 24.31× |
| 2023-12-31 | $89.94M | $3.63M | $88.16M | (m) | (m) | (m) | (m) | (m) | 24.76× |
| 2022-12-31 | $42.81M | $2.10M | $42.09M | (m) | (m) | (m) | (m) | (m) | 20.35× |
| 2021-12-31 | $17.43M | $1.64M | $17.34M | (m) | (m) | (m) | (m) | (m) | 10.66× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.